327 related articles for article (PubMed ID: 28933616)
1. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
Inchingolo R; Condoluci C; Smargiassi A; Mastrobattista A; Boccabella C; Comes A; Golfi N; Richeldi L
Expert Opin Pharmacother; 2017 Oct; 18(15):1583-1594. PubMed ID: 28933616
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targets in idiopathic pulmonary fibrosis.
Kolb M; Bonella F; Wollin L
Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
George PM; Wells AU
Expert Rev Clin Pharmacol; 2017 May; 10(5):483-491. PubMed ID: 28266906
[TBL] [Abstract][Full Text] [Related]
4. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
5. An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis.
Aryal S; Nathan SD
Expert Opin Emerg Drugs; 2018 Jun; 23(2):159-172. PubMed ID: 29718783
[TBL] [Abstract][Full Text] [Related]
6. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2016 Oct; 40():95-103. PubMed ID: 27481628
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.
Raghu G
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29074545
[TBL] [Abstract][Full Text] [Related]
8. Update in diffuse parenchymal lung disease, 2013.
Rosas IO; Kaminski N
Am J Respir Crit Care Med; 2015 Feb; 191(3):270-4. PubMed ID: 25635490
[TBL] [Abstract][Full Text] [Related]
9. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
10. Current and Future Idiopathic Pulmonary Fibrosis Therapy.
Richeldi L; Baldi F; Pasciuto G; Macagno F; Panico L
Am J Med Sci; 2019 May; 357(5):370-373. PubMed ID: 31010462
[TBL] [Abstract][Full Text] [Related]
11. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
Spagnolo P; Maher TM; Richeldi L
Pharmacol Ther; 2015 Aug; 152():18-27. PubMed ID: 25946646
[TBL] [Abstract][Full Text] [Related]
13. The safety of new drug treatments for idiopathic pulmonary fibrosis.
Fletcher S; Jones MG; Spinks K; Sgalla G; Marshall BG; Limbrey R; Richeldi L
Expert Opin Drug Saf; 2016 Nov; 15(11):1483-1489. PubMed ID: 27532218
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis.
Sathiyamoorthy G; Sehgal S; Ashton RW
South Med J; 2017 Jun; 110(6):393-398. PubMed ID: 28575896
[TBL] [Abstract][Full Text] [Related]
15. Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.
Jo HE; Troy LK; Keir G; Chambers DC; Holland A; Goh N; Wilsher M; de Boer S; Moodley Y; Grainge C; Whitford H; Chapman S; Reynolds PN; Glaspole I; Beatson D; Jones L; Hopkins P; Corte TJ
Respirology; 2017 Oct; 22(7):1436-1458. PubMed ID: 28845557
[TBL] [Abstract][Full Text] [Related]
16. Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Clarke DL; Murray LA; Crestani B; Sleeman MA
Pharmacol Ther; 2017 Jan; 169():35-46. PubMed ID: 27612548
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological management of IPF.
Borie R; Justet A; Beltramo G; Manali ED; Pradère P; Spagnolo P; Crestani B
Respirology; 2016 May; 21(4):615-25. PubMed ID: 27072575
[TBL] [Abstract][Full Text] [Related]
18. Shedding light on developmental drugs for idiopathic pulmonary fibrosis.
Spagnolo P; Bonella F; Ryerson CJ; Tzouvelekis A; Maher TM
Expert Opin Investig Drugs; 2020 Aug; 29(8):797-808. PubMed ID: 32538186
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence.
Robalo-Cordeiro C; Campos P; Carvalho L; Borba A; Clemente S; Freitas S; Furtado S; Jesus JM; Leal C; Marques A; Melo N; Souto-Moura C; Neves S; Sousa V; Santos A; Morais A
Rev Port Pneumol (2006); 2017; 23(5):287-293. PubMed ID: 28668400
[TBL] [Abstract][Full Text] [Related]
20. Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Hayton C; Chaudhuri N
Drugs Aging; 2017 Sep; 34(9):647-653. PubMed ID: 28861727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
